Clinical Report: Correction on Immunotherapy After Disease Progression

Background

Immunotherapy has emerged as a significant treatment modality for advanced and locally advanced lung cancer. Understanding the efficacy and safety of continuing immunotherapy beyond disease progression is crucial.

Data Highlights

No numerical or trial data is presented in the correction notice.

Key Findings

• Correction acknowledges Hua Lan as an equal contributing author.
• The original study evaluated the clinical benefit and safety of immunotherapy beyond progression.
• Immunotherapy is a critical treatment option for advanced lung cancer.
• Accurate authorship is essential for the integrity of clinical research.

Clinical Implications

Accurate authorship is essential for the integrity of clinical research.

Conclusion

The correction emphasizes the importance of accurate authorship in clinical research.

Related Resources & Content

1. Huangfu R, Lan H, Li R, Hou K, Ping Y, Frontiers Production Office, 2026 -- Correction: Clinical benefit and safety of immunotherapy beyond progression in advanced and locally advanced lung cancer: a real-world cohort study
2. The ASCO Post — Highlights From the ESMO Congress 2022
3. The ASCO Post — Expert Point of View: Giuseppe Curigliano, MD, PhD
4. The ASCO Post — Combination Immunotherapy for Lung Cancer: The Wave of the Future
5. The ASCO Post — Neoadjuvant Immunotherapy May Benefit Patients With Early-Stage NSCLC
6. Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.1 | Journal of Clinical Oncology
7. Frontiers | Clinical benefit and safety of immunotherapy beyond progression in advanced and locally advanced lung cancer: a real-world cohort study
8. Immunotherapy rechallenge after progression in non-small cell lung cancer: A systematic review and network meta-analysis - PMC